Silence Therapeutics granted two US patents
Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.
Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.
The patents, which are for both its interfering RNA molecules and lipid complexes used in drug delivery, will extend Silence's intellectual property in these areas of research.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"We welcome the decision of the USPTO on drug delivery as an appreciation of Silence's contribution. With this patent, Silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with siRNA and miRNA being only two of them."
The share price was down 6.25% to 3.15p by 13:18.
NR
-
Revealed: The 10 UK locations which could see the biggest house price growth in 2026Scotland leads the way for house price growth in 2026 according to Zoopla, but what regions will do the best in 2026?
-
Could pensions inheritance tax rule change create liquidity crisis for Sippholders?Pension inheritance tax rule changes from April 2027 could create a liquidity crisis for some self-invested personal pensions (Sipps) holding commercial property. We reveal what you can do to mitigate the impact.
